Jaskiewicz K, Louw J A, Marks I N
Department of Anatomical Pathology, University of Cape Town Medical School, Observatory, South Africa.
Dig Dis Sci. 1993 May;38(5):937-43. doi: 10.1007/BF01295924.
Thirty-six patients with nonhealing or recurrent duodenal ulcers (DU) were treated with omeprazole; 20 mg/day for one month followed by triple therapies (metronidazole, 400 mg three times a day, tetracycline, 500 mg four times a day with either colloidal bismuth, 120 mg four times a day or sucralfate 1 g four times a day. At least two gastric mucosal samples were collected from the antral portion of the stomach and from the duodenum before and immediately after omeprazole therapy and four weeks after completion of triple therapies. Samples were fixed in buffered formaldehyde and glutaraldehyde and examined histologically and histochemically for inflammation, density of H. pylori colonization, and immunohistochemically for the density of gastrin-secreting cells, immunoglobulins (IgA, IgG, IgM), kappa and lambda light chains and T-lymphocyte population. H. pylori colonization of the antral mucosa before treatment was noted in 100% and active gastritis in 86% of patients. The histologically assessed clearance rate after omeprazole treatment was 47.3%, and after triple therapies, 69.5%. The prevalence of gastritis was observed in 63.9% and 33.3% respectively. All therapies were associated with an accumulation of serous fluid, increased population of lymphocytes and plasma cells, and secretion of immunoglobulins, particularly IgG and IgM in the upper part of the lamina propria. These changes, together with increased numbers of T lymphocytes within the crypt epithelium and the lamina propria, were associated with the presence of H. pylori organisms.(ABSTRACT TRUNCATED AT 250 WORDS)
36例十二指肠溃疡(DU)不愈合或复发患者接受奥美拉唑治疗;每天20毫克,持续1个月,随后进行三联疗法(甲硝唑,每日3次,每次400毫克;四环素,每日4次,每次500毫克,同时联用胶体铋,每日4次,每次120毫克或硫糖铝,每日4次,每次1克)。在奥美拉唑治疗前、治疗刚结束时以及三联疗法完成后4周,至少从胃窦部和十二指肠采集两份胃黏膜样本。样本用缓冲甲醛和戊二醛固定,进行组织学和组织化学检查以评估炎症、幽门螺杆菌定植密度,并用免疫组织化学检查胃泌素分泌细胞密度、免疫球蛋白(IgA、IgG、IgM)、κ轻链和λ轻链以及T淋巴细胞群体。治疗前100%的患者胃窦黏膜有幽门螺杆菌定植,86%的患者有活动性胃炎。奥美拉唑治疗后组织学评估的清除率为47.3%,三联疗法后为69.5%。胃炎患病率分别为63.9%和33.3%。所有治疗均伴有浆液性液体积聚、淋巴细胞和浆细胞数量增加以及免疫球蛋白分泌增加,尤其是固有层上部的IgG和IgM。这些变化,连同隐窝上皮和固有层内T淋巴细胞数量增加,与幽门螺杆菌的存在有关。(摘要截断于250字)